Buy & Sell Analog Devices, Inc. (ADI) – Analog Devices, Inc. Price Today
Aura AI Summary
Key Stats
- $203.82BMarket Cap
- TechnologySector
- -15.99%3M Drawdown
- $208.45BEnterprise Value
- 0.97%Dividend Yield
- 69 daysTypical Hold Time
Analog Devices, Inc. (ADI) is currently valued at a market capitalization of $203.82B, with an enterprise value of $208.45B. Over the past 52 weeks, Analog Devices, Inc. has traded between a low of $210.47 and a high of $432.39, highlighting its annual price range. Over the past three months, Analog Devices, Inc. has recorded a drawdown of -15.99%, reflecting recent price volatility. Analog Devices, Inc. offers a dividend yield of 0.97%, with the most recent dividend of $0.99 paid on 08 Dec 25. On average, investors hold Analog Devices, Inc. for approximately 69 days, indicating typical investor behavior on the platform.
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Most Recent News
SuperCom wins new electronic monitoring contract in Nevada, expanding to 17 U.S. states since mid-2024.
SuperCom secured a new electronic monitoring contract in Nevada, marking its entry into the state and expanding its U.S. presence to 17 states since mid-2024. The contract involves deploying SuperCom's PureOne GPS technology for offender supervision,...
Sitryx Therapeutics to present at major healthcare investor conferences in June 2026
Sitryx Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced its management will participate in three key investor conferences in June 2026: Jefferies Global Healthcare Conference in New Y...
Regeneron shares drop 10% after Phase 3 melanoma trial misses primary endpoint.
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
